3 Biotechs With Upcoming Data To Be Presented At Conferences

  • Biotech stocks tend to have strong movement when their respective companies have binary events upcoming in short order.
  • These events are also known as "catalysts."
  • These catalysts contain, but are not limited to; clinical data, PDFUA dates, and FDA advisory committee meetings.
  • In this write up, we feature 3 companies with upcoming data to be presented at data conferences this week.

We start our biotech catalyst driven trades we feel may provide upside with Cytokinetics (CYTK), which looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. As the lead investigator had highlighted in his presentation of the data, 65.8% of patients were still in the active cohort as compared to 87.8% in placebo at the 24-week follow-up. Early dropouts were driven by neurological toxicity such as dizziness, fatigue and nausea. Although the effect size was not significant in the study, there were some small signs of slowing the rate of decline in slow vital capacity.

Green plants in large sealed beakers in a laboratory

The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. It is designed not to cross the blood-brain barrier, and the phase 1 study in healthy patients shows that it is far more tolerable. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function. Upcoming this week on June 16th, the company will be presenting initial findings from the phase 2 study of Reldesemtiv in spinal muscular atrophy (SMA). The study will enroll at two dose levels, 150mg and 450mg in both ambulatory and non-ambulatory patients who are over the age of 12.

This is an exploratory trial with many end-points, but our primary focus is on respiratory outcomes. We will be watching to see not only if the drug is well tolerated in a target patient population, but also if the diaphragm function will improve more noticeably. A benefit here should change sentiments towards the name, and should get the stock price up to around, or over $12 a share. A longer shot outcome with more meaningful upside would also show benefit in motor function, such as the 6-meter walk test.

1 2 3 4
View single page >> |

Disclosure: Long $CYTK, $AFMD.

This article/video is intended for informational and entertainment use only, and should not be construed as professional investment advice. They are our opinions ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.